[HTML][HTML] Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
Journal of Clinical Oncology, 2011•ncbi.nlm.nih.gov
Purpose To determine the maximum-tolerated dose (MTD), safety, pharmacokinetic and
pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in
patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia
(CMML), or acute myeloid leukemia (AML).
pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in
patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia
(CMML), or acute myeloid leukemia (AML).
Abstract
Purpose
To determine the maximum-tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
ncbi.nlm.nih.gov